Table 1 Baseline characteristics of the total population
|  | Total population (n = 2107) | MACCE (n = 187) | Non-MACCE (n = 1920) | P-value |
|---|---|---|---|---|
IR surrogates | ||||
 TyG index | 8.87 ± 0.60 | 9.30 ± 0.62 | 8.82 ± 0.58 | < 0.001 |
 VAI | 2.84 ± 1.98 | 3.95 ± 2.54 | 2.73 ± 1.88 | < 0.001 |
 CVAI | 132.18 ± 45.07 | 151.37 ± 45.35 | 130.31 ± 44.61 | < 0.001 |
 LAP | 51.04 ± 40.28 | 76.31 ± 55.99 | 48.58 ± 37.53 | < 0.001 |
 TG/HDL-C | 4.35 ± 2.86 | 5.74 ± 3.51 | 4.21 ± 2.75 | < 0.001 |
Age, years | 60.02 ± 9.03 | 61.25 ± 9.89 | 59.90 ± 8.93 | 0.073 |
Gender, female, n (%) | 591 (28.0) | 65 (34.8) | 526 (27.4) | 0.032 |
BMI, kg/m2 | 26.08 ± 3.21 | 26.43 ± 3.30 | 26.05 ± 3.20 | 0.115 |
WC, cm | 91.39 ± 12.39 | 95.24 ± 13.06 | 91.01 ± 12.26 | < 0.001 |
Heart rate, bpm | 69.80 ± 10.15 | 71.03 ± 10.40 | 69.68 ± 10.12 | 0.083 |
SBP, mmHg | 130.17 ± 16.47 | 129.79 ± 17.95 | 130.21 ± 16.33 | 0.741 |
DBP, mmHg | 76.94 ± 9.78 | 76.00 ± 10.26 | 77.03 ± 9.73 | 0.166 |
Smoking history, n (%) | 1195 (56.7) | 103 (55.1) | 1092 (56.9) | 0.636 |
Drinking history, n (%) | 495 (23.5) | 44 (23.5) | 451 (23.5) | 0.990 |
Family history of CAD, n (%) | 218 (10.3) | 14 (7.5) | 204 (10.6) | 0.179 |
Medical history, n (%) | ||||
 T2DM | 721 (34.2) | 89 (47.6) | 632 (32.9) | < 0.001 |
 Hypertension | 1305 (61.9) | 129 (69.0) | 1176 (61.3) | 0.038 |
 Previous MI | 440 (20.9) | 67 (35.8) | 373 (19.4) | < 0.001 |
 Previous PCI | 359 (17.0) | 45 (24.1) | 314 (16.4) | 0.007 |
 Previous stroke | 235 (11.2) | 31 (16.6) | 204 (10.6) | 0.014 |
 Previous PAD | 73 (3.5) | 6 (3.2) | 67 (3.5) | 0.841 |
Clinical diagnosis, n (%) | Â | Â | Â | 0.021 |
 NSTEMI | 1750 (83.1) | 43 (23.0) | 314 (16.4) |  |
 UA | 357 (16.9) | 144 (77.0) | 1606 (83.6) |  |
Laboratory tests | ||||
 TG, mmol/L | 1.71 ± 0.90 | 2.21 ± 1.07 | 1.66 ± 0.87 | < 0.001 |
 TC, mmol/L | 4.17 ± 1.04 | 4.38 ± 1.11 | 4.14 ± 1.03 | 0.003 |
 LDL-C, mmol/L | 2.52 ± 0.88 | 2.60 ± 0.90 | 2.51 ± 0.88 | 0.208 |
 HDL-C, mmol/L | 0.99 ± 0.23 | 0.95 ± 0.22 | 0.99 ± 0.23 | 0.029 |
 hs-CRP, mg/L | 1.27 (0.57, 3.26) | 1.46 (0.66, 3.95) | 1.25 (0.55, 3.18) | 0.084 |
 Creatinine, μmol/L | 75.86 ± 16.61 | 75.30 ± 15.85 | 75.91 ± 16.69 | 0.630 |
 eGFR, mL/min/1.73 m2 | 93.62 ± 19.95 | 92.22 ± 20.40 | 93.75 ± 19.91 | 0.317 |
 Uric acid, μmol/L | 344.87 ± 80.82 | 351.16 ± 82.23 | 344.26 ± 80.67 | 0.265 |
 FBG, mmol/L | 6.11 ± 1.88 | 7.33 ± 3.08 | 5.99 ± 1.67 | < 0.001 |
 HbA1c, % | 6.26 ± 1.18 | 6.90 ± 1.49 | 6.19 ± 1.13 | < 0.001 |
LVEF, % | 64.02 ± 6.69 | 62.53 ± 8.04 | 64.16 ± 6.53 | 0.008 |
Medications at admission, n (%) | ||||
 ACEI/ARB | 470 (22.3) | 46 (24.6) | 424 (22.1) | 0.430 |
 DAPT | 632 (30.0) | 58 (31.0) | 574 (29.9) | 0.750 |
 Aspirin | 1105 (52.4) | 103 (55.1) | 1002 (52.2) | 0.450 |
 P2Y12 inhibitors | 672 (31.9) | 64 (34.2) | 608 (31.7) | 0.474 |
 β-blocker | 468 (22.2) | 51 (27.3) | 417 (21.7) | 0.081 |
 Statins | 649 (30.8) | 64 (34.2) | 585 (30.5) | 0.288 |
 Oral antidiabetic agents | 375 (17.8) | 48 (25.7) | 327 (17.0) | 0.003 |
 Insulin | 198 (9.4) | 29 (15.5) | 169 (8.8) | 0.003 |
Medications at discharge, n (%) | ||||
 ACEI/ARB | 1455 (69.1) | 154 (82.4) | 1301 (67.8) | < 0.001 |
 DAPT | 2106 (100.0) | 187 (100.0) | 1919 (99.9) | > 0.999 |
 Aspirin | 2106 (100.0) | 187 (100.0) | 1919 (99.9) | > 0.999 |
 P2Y12 inhibitors | 2107 (100.0) | 187 (100.0) | 1920 (100.0) | 1.000 |
 β-blocker | 1910 (90.7) | 171 (91.4) | 1739 (90.6) | 0.696 |
 Statins | 2065 (98.0) | 183 (97.9) | 1882 (98.0) | 0.881 |
 Oral antidiabetic agents | 372 (17.7) | 47 (25.1) | 325 (16.9) | 0.005 |
 Insulin | 190 (9.0) | 27 (14.4) | 163 (8.5) | 0.007 |
Coronary procedural information | ||||
 LM disease, n (%) | 93 (4.4) | 18 (9.6) | 75 (3.9) | < 0.001 |
 Three-vessel disease, n (%) | 631 (29.9) | 77 (41.2) | 554 (28.9) | < 0.001 |
 Chronic total occlusion, n (%) | 277 (13.1) | 39 (20.9) | 238 (12.4) | 0.001 |
 Diffuse lesion, n (%) | 508 (24.1) | 55 (29.4) | 453 (23.6) | 0.076 |
 Bifurcation lesion, n (%) | 435 (20.6) | 40 (21.4) | 395 (20.6) | 0.792 |
 SYNTAX score | 10.62 ± 5.46 | 12.84 ± 6.23 | 10.40 ± 5.33 | < 0.001 |
 Target vessel territory, n (%) | ||||
  LM | 52 (2.5) | 8 (4.3) | 44 (2.3) | 0.095 |
  LAD | 1379 (65.4) | 115 (61.5) | 1264 (65.8) | 0.234 |
  LCX | 724 (34.4) | 61 (32.6) | 663 (34.5) | 0.599 |
  RCA | 895 (42.5) | 90 (48.1) | 805 (41.9) | 0.101 |
 Complete revascularization, n (%) | 1237 (58.7) | 90 (48.1) | 1147 (59.7) | 0.002 |
 Number of stents | 1.98 ± 1.27 | 2.09 ± 1.34 | 1.97 ± 1.27 | 0.254 |